Venrock-backed Inscripta is taking an unusual business approach. : CRISPR gene editing is widely regarded as one of the most significant advances in the life sciences in decades. The technology, which allows scientists to slice and dice bits of genetic code with the help of special CRISPR enzymes, has implications in everything from curing devastating diseases to making pigs less fatty to creating bigger, tastier, genetically modified tomatoes. But existing CRISPR technologies are so red-hot that they’ve prompted an epic intellectual property showdown between the Broad Institute of MIT and Harvard University’s Feng Zhang and U.C.